(Circulation. 2000;102:1950.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Homozygous Mutation in Cardiac Troponin T
Implications for Hypertrophic Cardiomyopathy
From the Cardiovascular Division (C.Y.H., C.E.S.), Brigham and Women’s Hospital, Harvard Medical School and Howard Hughes Medical Institute, Boston, Mass; The Cleveland Clinic Foundation (H.M.L., C.F.F.), Cleveland, Ohio; Cardiac Unit (R.D.), Massachusetts General Hospital, Boston, Mass; and Department of Genetics and Howard Hughes Medical Institute (J.G.S.), Harvard Medical School, Boston, Mass.
Correspondence to Christine E. Seidman, MD, Department of Genetics, Alpert Building, Harvard Medical School, 200 Longwood Ave, Boston, MA 02115. E-mail cseidman{at}rascal.med.harvard.edu
Background—Mutations in the gene
that encode cardiac troponin T (cTnT) account for 
15% of cases of
familial hypertrophic cardiomyopathy (HCM). These
mutations are associated with a particularly severe form of HCM
characterized by a high incidence of sudden death and a poor overall
prognosis, despite subclinical or mild left ventricular
hypertrophy.
Methods and Results—We evaluated a family with HCM and multiple occurrences of sudden death in children. DNA samples were isolated from peripheral blood or paraffin-embedded tissue, and all protein-encoding exons of the cTnT gene were sequenced. A mutation was identified in exon 11 and is predicted to substitute a phenylalanine-for-serine mutation at residue 179 (Ser179Phe) in cTnT. Both parents and 3 of 4 surviving and clinically unaffected children were heterozygous for this mutation; another clinically unaffected child did not carry the mutation. Genetic analysis of DNA from a child who died suddenly at age 17 years demonstrated he was homozygous for this mutation. A review of his echocardiogram revealed profound left and right ventricular hypertrophy.
Conclusions—An homozygous Ser179Phe mutation in cTnT causes a severe form of HCM characterized by striking morphological abnormalities and juvenile lethality. In contrast, the natural history of the heterozygous mutation is benign. These studies emphasize the relevance of genetic diagnosis in hypertrophic cardiomyopathy and provide a new perspective on the clinical consequences of troponin T mutations.
Key Words: cardiomyopathy • cardiac troponin T • genetics
This article has been cited by other articles:
 |
|
 |
|
  J. M. Bos, J. A. Towbin, and M. J. Ackerman Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., July 14, 2009; 54(3): 201 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kelly and C. Semsarian Multiple Mutations in Genetic Cardiovascular Disease: A Marker of Disease Severity? Circ Cardiovasc Genet, April 1, 2009; 2(2): 182 - 190. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Olivotto, F. Girolami, M. J. Ackerman, S. Nistri, J. M. Bos, E. Zachara, S. R. Ommen, J. L. Theis, R. A. Vaubel, F. Re, et al. Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy Mayo Clin. Proc., June 1, 2008; 83(6): 630 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tsoutsman, M. Kelly, D. C.H. Ng, J.-E. Tan, E. Tu, L. Lam, M. A. Bogoyevitch, C. E. Seidman, J.G. Seidman, and C. Semsarian Severe Heart Failure and Early Mortality in a Double-Mutation Mouse Model of Familial Hypertrophic Cardiomyopathy Circulation, April 8, 2008; 117(14): 1820 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Richard, E. Villard, P. Charron, and R. Isnard The Genetic Bases of Cardiomyopathies J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A79 - A89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R H Lekanne Deprez, J J Muurling-Vlietman, J Hruda, M J H Baars, L C D Wijnaendts, I Stolte-Dijkstra, M Alders, and J M van Hagen Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene J. Med. Genet., October 1, 2006; 43(10): 829 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Perkins, S. L. Van Driest, E. G. Ellsworth, M. L. Will, B. J. Gersh, S. R. Ommen, and M. J. Ackerman Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy Eur. Heart J., November 2, 2005; 26(22): 2457 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Ingles, A Doolan, C Chiu, J Seidman, C Seidman, and C Semsarian Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling J. Med. Genet., October 1, 2005; 42(10): e59 - e59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Van Driest, S. R. Ommen, A. J. Tajik, B. J. Gersh, and M. J. Ackerman Sarcomeric Genotyping in Hypertrophic Cardiomyopathy Mayo Clin. Proc., April 1, 2005; 80(4): 463 - 469. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Harada and J. D. Potter Familial Hypertrophic Cardiomyopathy Mutations from Different Functional Regions of Troponin T Result in Different Effects on the pH and Ca2+ Sensitivity of Cardiac Muscle Contraction J. Biol. Chem., April 9, 2004; 279(15): 14488 - 14495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Nabel Cardiovascular Disease N. Engl. J. Med., July 3, 2003; 349(1): 60 - 72. [Full Text] [PDF]
|
|
|
|
|
|
A.J. Marian and R. Roberts To Screen or Not Is Not the Question-- It Is When and How to Screen Circulation, May 6, 2003; 107(17): 2171 - 2174. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Marian On predictors of sudden cardiac death in hypertrophic cardiomyopathy J. Am. Coll. Cardiol., March 19, 2003; 41(6): 994 - 996. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Van Driest, M. J. Ackerman, S. R. Ommen, R. Shakur, M. L. Will, R. A. Nishimura, A. J. Tajik, and B. J. Gersh Prevalence and Severity of "Benign" Mutations in the {beta}-Myosin Heavy Chain, Cardiac Troponin T, and {alpha}-Tropomyosin Genes in Hypertrophic Cardiomyopathy Circulation, December 10, 2002; 106(24): 3085 - 3090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Seidman Genetic Causes of Inherited Cardiac Hypertrophy: Robert L. Frye Lecture Mayo Clin. Proc., December 1, 2002; 77(12): 1315 - 1319. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Arad, J.G. Seidman, and C. E. Seidman Phenotypic diversity in hypertrophic cardiomyopathy Hum. Mol. Genet., October 1, 2002; 11(20): 2499 - 2506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fatkin and R. M. Graham Molecular Mechanisms of Inherited Cardiomyopathies Physiol Rev, October 1, 2002; 82(4): 945 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Olson, M. L. Karst, F. G. Whitby, and D. J. Driscoll Myosin Light Chain Mutation Causes Autosomal Recessive Cardiomyopathy With Mid-Cavitary Hypertrophy and Restrictive Physiology Circulation, May 21, 2002; 105(20): 2337 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. M. Hernandez, P. R. Housmans, and J. D. Potter Plasticity in Skeletal, Cardiac, and Smooth Muscle: Invited Review: Pathophysiology of cardiac muscle contraction and relaxation as a result of alterations in thin filament regulation J Appl Physiol, March 1, 2001; 90(3): 1125 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Knollmann, S. A. Blatt, K. Horton, F. de Freitas, T. Miller, M. Bell, P. R. Housmans, N. J. Weissman, M. Morad, and J. D. Potter Inotropic Stimulation Induces Cardiac Dysfunction in Transgenic Mice Expressing a Troponin T (I79N) Mutation Linked to Familial Hypertrophic Cardiomyopathy J. Biol. Chem., March 23, 2001; 276(13): 10039 - 10048. [Abstract] [Full Text] [PDF]
|
|